- Home
- LLY
as 06-28-2024 4:00pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 834.9B | IPO Year: | N/A |
| Target Price: | $806.45 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | 0.57% | Dividend Payout Frequency: | Quarterly |
| EPS: | 6.79 | EPS Growth: | 7.95 |
| 52 Week Low/High: | $434.34 - $915.54 | Next Earning Date: | 08-06-2024 |
| Revenue: | $35,932,100,000 | Revenue Growth: | 29.76% |
| Revenue Growth (this year): | 27.44% | Revenue Growth (next year): | 23.36% |
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 24 '24 | Sell | $903.42 | 1,200 | $1,084,101.60 | 97,556,910 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 24 '24 | Sell | $902.30 | 16,029 | $14,462,966.70 | 97,558,110 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 20 '24 | Sell | $904.25 | 200 | $180,849.00 | 97,574,139 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 20 '24 | Sell | $903.50 | 2,919 | $2,637,322.34 | 97,574,339 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 20 '24 | Sell | $902.25 | 6,552 | $5,911,561.66 | 97,577,258 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $892.14 | 46 | $41,038.44 | 97,583,810 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $891.54 | 1,300 | $1,158,998.10 | 97,583,856 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $890.50 | 6,121 | $5,450,768.86 | 97,585,156 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $889.36 | 15,342 | $13,644,607.15 | 97,591,277 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $888.52 | 18,293 | $16,253,641.48 | 97,606,619 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $887.47 | 38,194 | $33,895,876.40 | 97,624,912 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $886.60 | 17,513 | $15,527,095.85 | 97,663,106 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $885.58 | 27,351 | $24,221,361.83 | 97,680,619 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $884.56 | 11,820 | $10,455,499.20 | 97,707,970 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $883.43 | 22,282 | $19,684,676.39 | 97,719,790 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 17 '24 | Sell | $882.45 | 36,716 | $32,400,144.35 | 97,742,072 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 14 '24 | Sell | $883.38 | 2,659 | $2,348,899.44 | 97,778,788 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 14 '24 | Sell | $882.28 | 12,363 | $10,907,590.55 | 97,781,447 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 10 '24 | Sell | $870.13 | 579 | $503,805.27 | 97,793,810 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 10 '24 | Sell | $869.22 | 1,500 | $1,303,822.50 | 97,794,389 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 10 '24 | Sell | $868.21 | 2,600 | $2,257,335.60 | 97,795,889 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 10 '24 | Sell | $867.03 | 3,117 | $2,702,538.74 | 97,798,489 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 10 '24 | Sell | $865.89 | 1,780 | $1,541,280.64 | 97,801,606 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 10 '24 | Sell | $865.06 | 13,415 | $11,604,793.32 | 97,803,386 | SEC Form 4 |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jun 10 '24 | Sell | $863.81 | 759 | $655,634.83 | 97,816,801 | SEC Form 4 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
This Is Massive News for Eli Lilly Investors
Motley Fool
a day ago
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.
Insider Monkey
2 days ago
Eli Lilly and Company (LLY): A Good Growth Stock To Buy Now According to Billionaire Ray Dalio
Yahoo Finance Video
2 days ago
How Medicare drug price negotiations could hit pharma stocks
Zacks
2 days ago
HIMS Stock Tumbles: Here's Why It's a Buy Right Now
Motley Fool
2 days ago
Stock Split Watch: Is Eli Lilly Next?
Investor's Business Daily
3 days ago
Eli Lilly Has Sprinted 55% Higher This Year — Is It A Buy On The Weight-Loss Opportunity?
Barrons.com
3 days ago
ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn’t Be.
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.